# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Central Nervous System Germ Cell Tumor
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** mir214_bcl2l11_cisplatin_response_candidate
- **Hypothesis Label:** miR-214-3p–BCL2L11 Cisplatin-Response Candidate
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: mir214_bcl2l11_cisplatin_response_candidate
hypothesis_label: miR-214-3p–BCL2L11 Cisplatin-Response Candidate
status: EMERGING
applies_to_subtypes:
- Central Nervous System Nongerminomatous Germ Cell Tumor
description: 'In a subset of malignant NGGCT, altered regulation of the miR-199/214 cluster may increase
  miR-214-3p, reduce the pro-apoptotic protein BCL2L11/BIM, and shift apoptosis and survival after cisplatin
  exposure. This is a candidate response-modifying chain: the current causal evidence comes from forced
  expression in one extracranial embryonal-carcinoma cell line and does not establish endogenous or intrinsic
  causality or distinguish resistant from sensitive CNS NGGCT in patients.'
evidence:
- reference: PMID:29036598
  reference_title: Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance
    in pediatric intracranial nongerminomatous malignant germ cell tumors.
  supports: PARTIAL
  evidence_source: HUMAN_CLINICAL
  snippet: The expression levels of 97 genes and 8 miRNAs were correlated with promoter DNA methylation
    and hydroxymethylation status, such as the miR-199/-214 cluster
  explanation: Human tumor multi-omic analysis links the miR-199/214 cluster to methylation state, but
    it does not compare longitudinally resistant and sensitive patient tumors.
- reference: PMID:29036598
  reference_title: Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance
    in pediatric intracranial nongerminomatous malignant germ cell tumors.
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: Overexpresssion of miR-214-3p in NCCIT cells leads to reduced expression of the pro-apoptotic
    protein BCL2-like 11 and induces cisplatin resistance.
  explanation: The cell-line perturbation supports the proposed miR-214-3p to BCL2L11 to cisplatin-survival
    chain in vitro.
notes: This is a cisplatin-response candidate, not a validated intrinsic-tolerance mechanism or clinical
  resistance biomarker. NCCIT is not a patient-derived CNS NGGCT model, and the report does not establish
  longitudinal enrichment, in-vivo necessity, or reversal of clinical resistance.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Issue-Specific Scope and Adjudication Requirements

For hypothesis `mir214_bcl2l11_cisplatin_response_candidate`, restrict the target
population to viable malignant pediatric/AYA intracranial NGGCT, especially
embryonal-carcinoma-like components. Exclude mature teratoma/GTS, pure germinoma,
generic multimodal treatment failure, carboplatin, and radiotherapy unless each is
analyzed separately as a competing context rather than evidence for
cisplatin-specific resistance.

Adjudicate these three claims independently:

1. Endogenous miR-214-3p is elevated in clinically cisplatin-resistant CNS tumor
   cells or paired diagnosis-to-failure specimens.
2. miR-214-3p directly represses BCL2L11/BIM in this disease context.
3. That repression causes cisplatin-specific survival rather than nonspecific
   viability, differentiation, or stress effects.

The seed study (PMID:29036598) reports methylation/expression correlation and
forced miR-214-3p overexpression in NCCIT cells. NCCIT is derived from an adult
male mediastinal mixed germ-cell tumor, not a CNS tumor, and forced
overexpression may be supraphysiologic. Do not describe that study as evidence
of endogenous necessity, a clinically resistant-versus-sensitive CNS comparison,
or a rescue experiment.

Actively compare differentiation-associated methylation, other miR-214 targets,
BCL2L11-independent apoptosis, platinum transport/detoxification, DNA repair,
TP53 and PI3K-AKT signaling, exposure differences, and histology confounding.

Strong support would require paired diagnosis-relapse or resistant-sensitive CNS
specimens; endogenous miR-214 perturbation; AGO2 occupancy or seed-mutant 3'UTR
testing; BCL2L11 knockdown phenocopy plus miRNA-insensitive BCL2L11 rescue; at
least two patient-derived intracranial models; orthotopic validation; and
cisplatin-versus-non-platinum controls. Treat failure of endogenous perturbation
or rescue, absent direct binding, an effect confined to supraphysiologic NCCIT
overexpression, or disappearance of a clinical association after exposure and
histology adjustment as refuting or sharply qualifying the corresponding claim.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.

**Provider:** openscientist
**Generated:** 2026-07-26T09:56:55.186601

1. PMID:29036598
2. PMID:41998312
3. PMID:35171328
4. PMID:24465927
5. PMID:18199536
6. PMID:28290615
7. PMID:16778834
8. PMID:23302226
9. PMID:34769213
10. PMID:33823933
11. PMID:31045925
12. PMID:25546083
13. PMID:20811155
14. PMID:35442716
15. PMID:32642701
16. PMID:22718761
17. PMID:23625774
